Expansion Opportunity AmbioPharm is executing a significant expansion in South Carolina and Aiken County, including a new modular manufacturing building and hiring hundreds of workers, signaling potential capacity to take on additional peptide API projects and scale production for clients.

Capacity Growth With investments totaling around 118.96 million and multiple facility enhancements, there is increased capacity for clinical and commercial peptide APIs, presenting opportunities for new client programs seeking reliable cGMP peptide manufacturing at scale.

Geographic Reach Operations in both North America and Asia (South Carolina and Shanghai) along with FDA-inspected facilities position AmbioPharm as a global CDMO capable of supporting multinational clinical trials and commercial launches.

Technology & Compliance Proven track record with FDA inspections and a focus on efficient manufacturing processes for peptide APIs suggests potential for collaboration on complex, high-purity peptide projects that require rigorous quality and regulatory alignment.

Financial & Stakeholders Mid-market revenue scale and ongoing expansion funded for growth indicate readiness to partner on long-term peptide development and manufacturing deals, including capacity-backed supply agreements and volume-based pricing.